These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 16465614

  • 1. Targeted therapy in rheumatoid arthritis.
    Köller MD.
    Wien Med Wochenschr; 2006 Jan; 156(1-2):53-60. PubMed ID: 16465614
    [Abstract] [Full Text] [Related]

  • 2. [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].
    Wollenhaupt J, Krüger K.
    Z Rheumatol; 2010 Sep; 69(7):618-25. PubMed ID: 20703488
    [Abstract] [Full Text] [Related]

  • 3. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ, Hyrich KL.
    BioDrugs; 2009 Sep; 23(2):111-24. PubMed ID: 19489652
    [Abstract] [Full Text] [Related]

  • 4. New therapies for treatment of rheumatoid arthritis.
    Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P.
    Lancet; 2007 Dec 01; 370(9602):1861-74. PubMed ID: 17570481
    [Abstract] [Full Text] [Related]

  • 5. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
    Manadan AM, Block JA.
    Am J Ther; 2008 Dec 01; 15(1):53-8. PubMed ID: 18223354
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD.
    Expert Opin Biol Ther; 2009 Dec 01; 9(12):1463-75. PubMed ID: 19916731
    [Abstract] [Full Text] [Related]

  • 7. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?
    Voll RE, Kalden JR.
    Ann N Y Acad Sci; 2005 Jun 01; 1051():799-810. PubMed ID: 16127017
    [Abstract] [Full Text] [Related]

  • 8. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis.
    Papagoras C, Voulgari PV, Drosos AA.
    Autoimmun Rev; 2010 Jun 01; 9(8):574-82. PubMed ID: 20433955
    [Abstract] [Full Text] [Related]

  • 9. [Indications and efficacy of biologics in inflammatory arthritis].
    Combe B.
    Bull Acad Natl Med; 2012 Oct 01; 196(7):1279-92; discussion 1293. PubMed ID: 23815014
    [Abstract] [Full Text] [Related]

  • 10. Sequential use of biologic therapy in rheumatoid arthritis.
    Buch MH.
    Curr Opin Rheumatol; 2010 May 01; 22(3):321-9. PubMed ID: 20190641
    [Abstract] [Full Text] [Related]

  • 11. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors].
    Swierkot J, Madej M.
    Pol Merkur Lekarski; 2011 Apr 01; 30(178):289-94. PubMed ID: 21595177
    [Abstract] [Full Text] [Related]

  • 12. Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?
    Nurmohamed MT.
    Drugs; 2009 Oct 22; 69(15):2035-43. PubMed ID: 19791825
    [Abstract] [Full Text] [Related]

  • 13. Interleukin-6: a new therapeutic target.
    Smolen JS, Maini RN.
    Arthritis Res Ther; 2006 Oct 22; 8 Suppl 2(Suppl 2):S5. PubMed ID: 16899109
    [Abstract] [Full Text] [Related]

  • 14. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
    Das S, Vital EM, Horton S, Bryer D, El-Sherbiny Y, Rawstron AC, Ponchel F, Emery P, Buch MH.
    Ann Rheum Dis; 2014 May 22; 73(5):909-12. PubMed ID: 24385201
    [Abstract] [Full Text] [Related]

  • 15. [New therapies for rheumatoid arthritis].
    Salgado E, Maneiro JR.
    Med Clin (Barc); 2014 Nov 18; 143(10):461-6. PubMed ID: 24461738
    [Abstract] [Full Text] [Related]

  • 16. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
    Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, Emery P, Keystone EC, Schiff MH, Mease P, van Riel PL, Fleischmann R, Weisman MH, Weinblatt ME.
    Ann Rheum Dis; 2007 Nov 18; 66 Suppl 3(Suppl 3):iii2-22. PubMed ID: 17934088
    [No Abstract] [Full Text] [Related]

  • 17. [Recent topics on new biological agents for treatment of rheumatoid arthritis].
    Saito K, Tanaka Y.
    Nihon Naika Gakkai Zasshi; 2008 Oct 10; 97(10):2418-23. PubMed ID: 19149039
    [No Abstract] [Full Text] [Related]

  • 18. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C, Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.
    Arthritis Rheum; 2007 May 10; 56(5):1417-23. PubMed ID: 17469098
    [Abstract] [Full Text] [Related]

  • 19. New therapies in the management of rheumatoid arthritis.
    Buch MH, Emery P.
    Curr Opin Rheumatol; 2011 May 10; 23(3):245-51. PubMed ID: 21427579
    [Abstract] [Full Text] [Related]

  • 20. [Management for TNF failure].
    Mukai M.
    Nihon Rinsho; 2007 Jul 10; 65(7):1299-307. PubMed ID: 17642247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.